The Board of BioSpecifics Technologies Corp. announced that George Gould, an independent director to the company's Audit Committee on an interim basis pending the appointment of a new independent director to the Board. The appointment of Mr. Gould to the Audit Committee satisfies NASDAQ Rule 5605(c)(2)(A), which requires the Audit Committee to have at least three independent directors.
BioSpecifics Technologies Corp.
Equities
BSTC
US0909311062
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |